KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Equity Average (2016 - 2025)

Ionis Pharmaceuticals has reported Equity Average over the past 16 years, most recently at $553.5 million for Q4 2025.

  • Quarterly results put Equity Average at $553.5 million for Q4 2025, down 11.49% from a year ago — trailing twelve months through Dec 2025 was $553.5 million (down 11.49% YoY), and the annual figure for FY2025 was $538.7 million, up 10.5%.
  • Equity Average for Q4 2025 was $553.5 million at Ionis Pharmaceuticals, down from $624.8 million in the prior quarter.
  • Over the last five years, Equity Average for IONS hit a ceiling of $740.7 million in Q1 2022 and a floor of $280.1 million in Q2 2024.
  • Median Equity Average over the past 5 years was $555.2 million (2021), compared with a mean of $541.8 million.
  • Biggest five-year swings in Equity Average: plummeted 63.18% in 2021 and later skyrocketed 97.68% in 2025.
  • Ionis Pharmaceuticals' Equity Average stood at $651.1 million in 2021, then dropped by 10.37% to $583.6 million in 2022, then plummeted by 39.85% to $351.1 million in 2023, then skyrocketed by 78.14% to $625.4 million in 2024, then fell by 11.49% to $553.5 million in 2025.
  • The last three reported values for Equity Average were $553.5 million (Q4 2025), $624.8 million (Q3 2025), and $553.7 million (Q2 2025) per Business Quant data.